Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 21, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
August 20, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing...
August 11, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ...
August 01, 2025 08:00 ET | Source: I-Mab Biopharma

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
July 17, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future...
July 14, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Present at the BTIG Virtual Biotechnology Conference

ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
July 02, 2025 11:15 ET | Source: I-Mab Biopharma

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1...
June 30, 2025 16:01 ET | Source: I-Mab Biopharma

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) --...
June 26, 2025 06:30 ET | Source: I-Mab Biopharma

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study ...
June 18, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

Virtual investor event planned for July 8th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at...